

United States Patent and Trademark Office

oh

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
08/915,658	08/21/1997	ЛGISH D TRIVEDI	MIO 0024 PA/40509.49	1803		
23368	23368 7590 06/29/2005			EXAMINER		
	E & SHOHL LLP	PERALTA, GINETTE				
ONE DAYTON CENTRE, ONE SOUTH MAIN STREET SUITE 1300			ART UNIT	PAPER NUMBER		
DAYTON, OH 45402-2023			2814	-		
			DATE MAILED: 06/29/2005			

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
08/915,658	TRIVEDI, JIGISH D	
Examiner	Art Unit	
Ginette Peralta	2814	مر

	Ginette Peralta	2814	* مي			
The MAILING DATE of this communication appe	ars on the cover sheet with the c	correspondence add	ress			
THE REPLY FILED 20 May 2005 FAILS TO PLACE THIS APP	LICATION IN CONDITION FOR A	LLOWANCE.				
 The reply was filed after a final rejection, but prior to or o this application, applicant must timely file one of the follo places the application in condition for allowance; (2) a No (3) a Request for Continued Examination (RCE) in comp following time periods: 	n the same day as filing a Notice o wing replies: (1) an amendment, a otice of Appeal (with appeal fee) in	f Appeal. To avoid at ffidavit, or other evide compliance with 37 (ence, which CFR 41.31; or			
	epires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no					
event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TW MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).						
Extensions of time may be obtained under 37 CFR 1.136(a). The date on been filed is the date for purposes of determining the period of extension a CFR 1.17(a) is calculated from: (1) the expiration date of the shortened stabove, if checked. Any reply received by the Office later than three month earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	and the corresponding amount of the fee. atutory period for reply originally set in the	The appropriate extension final Office action; or (2)	on fee under 37 as set forth in (b)			
 The Notice of Appeal was filed on A brief in com of filing the Notice of Appeal (37 CFR 41.37(a)), or any e Since a Notice of Appeal has been filed, any reply must be 	xtension thereof (37 CFR 41.37(e)), to avoid dismissal (of the appeal.			
AMENDMENTS	to a contract about the contract of the contra	£(11)	h			
 The proposed amendment(s) filed after a final rejection, They raise new issues that would require further co They raise the issue of new matter (see NOTE below) 	nsideration and/or search (see NO ow);	TE below);				
 (c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or (d) They present additional claims without canceling a corresponding number of finally rejected claims. 						
NOTE: (See 37 CFR 1.116 and 41.33(a))		sjected claims.				
4. The amendments are not in compliance with 37 CFR 1.	121. See attached Notice of Non-C	ompliant Amendmen	t (PTOL-324).			
 Applicant's reply has overcome the following rejection(s Newly proposed or amended claim(s) would be a the non-allowable claim(s). 		, timely filed amendo	nent canceling			
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is pro The status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: 31-49. Claim(s) withdrawn from consideration:		vill be entered and an	explanation of			
AFFIDAVIT OR OTHER EVIDENCE						
 The affidavit or other evidence filed after a final action, b because applicant failed to provide a showing of good ar and was not earlier presented. See 37 CFR 1.116(e). 	ut before or on the date of filing a N nd sufficient reasons why the affida	Notice of Appeal will <u>residence</u>	not be entered is necessary			
 The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to showing a good and sufficient reasons why it is necessal 	overcome <u>all</u> rejections under appe ry and was not earlier presented. S	al and/or appellant fa See 37 CFR 41.33(d)	nils to provide a (1).			
10. ☐ The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER						
 The request for reconsideration has been considered by <u>See Continuation Sheet.</u> 			ance because:			
12. Note the attached Information Disclosure Statement(s).13. Other:	(PTO/SB/08 or PTO-1449) Paper	No(s)				

Continuation of 11, does NOT place the application in condition for allowance because: Regarding applicant's argument that Chung et al. does not teach a first metal silicide, a second metal silicide, and an intermetallic compound which comprises metal from the first metal silicide and a metal from the second metal silicide since one skilled in the art would have to choose tungsten silicide from the possible choices and this negates anticipation, it is noted that the MPEP 2129 reads >"When a claim covers several structures or compositions, either generically or as alternatives, the claim is deemed anticipated if any of the structures or compositions within the scope of the claim is known in the prior art." Brown v. 3M, 265 F.3d 1349, 1351, 60 USPQ2d 1375, 1376 (Fed. Cir. 2001) and in MPEP 2131.02 that "however, when the species is clearly named, the species claim is anticipated no matter how many other species are additionally named. Ex parte A, 17 USPQ2d 1716 (Bd. Pat. App. & Inter. 1990) (The claimed compound was named in a reference which also disclosed 45 other compounds. The Board held that the comprehensiveness of the listing did not negate the fact that the compound claimed was specifically taught. The Board compared the facts to the situation in which the compound was found in the Merck Index, saying that "the tenth edition of the Merck Index lists ten thousand compounds. In our view, each and every one of those compounds is described' as that term is used in 35 U.S.C. § 102(a), in that publication."). Id. at 1718. See also In re Sivaramakrishnan, 673 F.2d 1383, 213 USPQ 441 (CCPA 1982) (The claims were directed to polycarbonate containing cadmium laurate as an additive. The court upheld the Board's finding that a reference specifically naming cadmium laurate as an additive amongst a list of many suitable salts in polycarbonate resin anticipated the claims. The applicant had argued that cadmium laurate was only disclosed as representative of the salts and was expected to have the same properties as the other salts listed while, as shown in the application, cadmium laurate had unexpected properties. The court held that it did not matter that the salt was not disclosed as being preferred, the reference still anticipated the claims and because the claim was anticipated, the unexpected properties were immaterial.). And furthermore, it is noted that the composite structure includes layer 38 since layer 38 is formed by treating layer 34, thus it is part of the composite structure.

HOAI PHAM
PRIMARY EXAMINER